DEVELOPMENT AND VALIDATION OF A SENSITIVE LC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF NIVOLUMAB AND RELATLIMAB IN RAT PLASMA
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56343Keywords:
LC-MS/MS, Rat plasma, Monoclonal antibodies, Immunotherapy, Simultaneous quantificationAbstract
Objective: This study aimed to develop and validate a sensitive, specific, and rapid LC-MS/MS method for the simultaneous quantification of nivolumab and relatlimab in rat plasma using daclizumab as internal standard (IS).
Methods: Chromatographic separation was achieved using a Luna C18 column (250 mm x 4.6 mm, 5µm) with an isocratic mobile phase consisting of ammonium formate of pH-2.5 adjusted with formic acid (A) and acetonitrile (B) in 40:60 (v/v) at a flow rate of 1.0 ml/min. Rat plasma samples were processed by liquid-liquid extraction with acetonitrile. Mass spectrometric detection was performed in positive electro spray ionization (ESI) mode using multiple reaction monitoring (MRM) for nivolumab and relatlimab. The method was validated per USFDA guidelines for selectivity, sensitivity, linearity, precision, accuracy, matrix effect, and stability.
Results: The method demonstrated excellent linearity over the concentration ranges of 12-480 ng/ml for nivolumab and 4-160 ng/ml for relatlimab, with a correlation coefficient (R²) of ≥0.999. The chromatographic separation was achieved with retention time of 3.35 min for nivolumab and 4.08 min for relatlimab. Accuracy, precision, recovery, matrix effect and stability results were found to be within the suitable limits. A MALDI-TOF mass spectrometry was used to study nivolumab, relatlimab at KDa 143.61→32.51, 145.27→21.76, and IS for m/z 144.04→ 35.61, which were ion pairs of mass analysis.
Conclusion: The developed LC-MS/MS method is highly sensitive, selective, and robust for the simultaneous estimation of nivolumab and relatlimab in rat plasma, making it suitable for preclinical and clinical pharmacokinetic investigations.
References
1. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24-34. doi: 10.1056/NEJMoa2109970, PMID 34986285.
2. Zhao Y, Hu Z, Bathena SP, Keidel S, Miller Moslin K, Statkevich P. Model-informed clinical pharmacology profile of a novel fixed-dose combination of nivolumab and relatlimab in adult and adolescent patients with solid tumors. Clin Cancer Res. 2024;30(14):3050-8. doi: 10.1158/1078-0432.CCR-23-2396, PMID 38295151.
3. Millet A, Khoudour N, Bros P, Lebert D, Picard G, Machon C. Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. Talanta. 2021;224:121889. doi: 10.1016/j.talanta.2020.121889, PMID 33379098.
4. Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using relativity-047 and CheckMate 067 trial data. J Clin Oncol. 2024 Aug 13;42(33):3926–34. doi: 10.1200/JCO.24.01125, PMID 39137386.
5. Colbert A, Umble Romero A, Prokop S, Chow VF, Wong T, DeSimone D. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs. mAbs. 2014;6(5):1178-89. doi: 10.4161/mabs.32114, PMID 25517303, PMCID PMC4623269.
6. Xu L, Zhou J, Eremin S, Dias AC, Zhang X. Development of ELISA and chemiluminescence enzyme immunoassay for quantification of histamine in drug products and food samples. Anal Bioanal Chem. 2020;412(19):4739-47. doi: 10.1007/s00216-020-02730-5, PMID 32488385.
7. Pandey S, Pandey P, Tiwari G, Tiwari R. Bioanalysis in drug discovery and development. Pharm Methods. 2010 Oct;1(1):14-24. doi: 10.4103/2229-4708.72223, PMID 23781412, PMCID PMC3658019.
8. Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R. An LC-MS/MS method for absolute quantification of nivolumab in human plasma: application to clinical therapeutic drug monitoring. Ther Drug Monit. 2018 Dec;40(6):716-24. doi: 10.1097/FTD.0000000000000558, PMID 30048380.
9. Kuzyk MA, Parker CE, Domanski D, Borchers CH. Development of MRM-based assays for the absolute quantitation of plasma proteins. Methods Mol Biol. 2013;1023:53-82. doi: 10.1007/978-1-4614-7209-4_4, PMID 23765619.
10. Alwadi M, Howaidi J, Alrajhi AM, Alnakhli A, Marei MA, Tailor IK. Safety and efficacy of azacitidine with venetoclax for newly diagnosed intensive chemotherapy ineligible and relapsed or refractory acute myeloid leukemia in Arab population: a single-center retrospective study. Blood. 2021;138(Suppl 1):4423. doi: 10.1182/blood-2021-153335.
11. Manoranjani M. LC-MS/MS method for simultaneous estimation of ethinyl estradiol and etonogestrel in rat plasma and its application to pharmacokinetic study. High Technol Lett. 2023;29:543-56.
12. Talari S, Vejendla A, Shetty RK. Development and validation of a UPLC-MS/MS method for the simultaneous determination of verapamil and trandolapril in rat plasma: application to a pharmacokinetic study. Curr Pharm Anal. 2022;18(3):291-304. doi: 10.2174/1573412917666210302145711.
13. Naveen VM, Veeraswami B, Srinivasa Rao G. High response bio-analytical validation approach of nadolol and Bendroϑlumethiazide by LC-MS/MS on Rat plasma. IJRPS. 2020;11(SPL4):2272-9. doi: 10.26452/ijrps.v11iSPL4.4454.
14. Malak Y, Al Bathish A, Gazy AA, El Jamal MK. RP-HPLC and chemometric methods for the determination of two anti-diabetic mixtures; metformin hydrochloride-canagliflozin and metformin hydrochloride-gliclazide in their pharmaceutical formulation. Int J Pharm Pharm Sci. 2020;12(2):83-94. doi: 10.22159/ijpps.2020v12i2.35415.
15. Priyadarshini I, Akila Devi D. Development and validation of an LC-MS/MS method for the determination of tenofovir and emtricitabine. Int J App Pharm. 2024;16(2):116-23. doi: 10.22159/ijap.2024v16i2.49667.
16. Harsha K, Ravisankar P, Kumar Konidala S, Srinivasa Babu P. Application of newly developed and validated LC-MS/MS method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma. J Chromatogr B. 2024;1241:124171. doi: 10.1016/j.jchromb.2024.124171.
17. Kamma Harsha Sri, Panchumarthy Ravisankar, Sathish Kumar Konidala, Srinivasa Babu Puttagunta. Quantification of Belzutifan in biological samples: LC-MS/MS method validation and pharmacokinetic study in rats. Biomed Chromatogr. 2025;39(9):e70168. doi: 10.1002/bmc.70168.
18. Raju GE, Pottendla S, Yaparthi S. Bioanalytical approach to Ensitrelvir estimation using Liquid chromatography tandem mass spectrometry and its application to pharmaceutical research. Asian J Pharm Clin Res. 2025;18(3):25-9. doi: 10.22159/ajpcr.2025v18i3.53760.
19. Rathore MK, Mohan Reddy TR. Tandem mass spectrometric method for the trace level determination of 2-aminopyridine: a potential genotoxic impurity in tenoxicam API. Int J Pharm Pharm Sci. 2024;16(4):50-6. doi: 10.22159/ijpps.2024v16i4.49902.
20. Thomas A, Varkey J. Development and validation of a new RP-HPLC analytical method for the determination of etodolac succinic acid co-crystals in spiked rabbit plasma. Int J Curr Pharm Sci. 2023;15(2):59-63. doi: 10.22159/ijcpr.2023v15i2.2098.
21. Raju GE, Pottendla S, Yaparthi S. Establishment and validation of LC-MS/MS technique for Lenacapavir quantification in rat plasma with application to pharmacokinetic assessment. J Appl Pharm Sci. 2025;15(5):112-20. doi: 10.7324/JAPS.2025.229006.
22. Raju GE, Pottendla S, Yaparthi S. Novel ultraperformance liquid chromatography method for concurrent estimation and pharmacokinetic analysis of favipiravir and molnupiravir in rat plasma. Asian J Pharm Clin Res. 2025;18(2):90-5. doi: 10.22159/ajpcr.2025v18i2.53662.
23. Sentat T, Lucida H, Widyati W, Nasif H. Development and validation of a bioanalytical method for the therapeutic drug monitoring of amikacin in human plasma using ultraperformance liquid chromatography tandem mass spectrometry. Int J Appl Pharm. 2024;16(1):140-4. doi: 10.22159/ijap.2024.v16s1.30.
24. Prabhakara Rao K, Namburi LA Amara babu, Kalyani Koganti, Babji Palakeeti, Koduri SV, Srinivas. Related substances method development and validation of an LC-MS/MS method for the quantification of Selexipag and its related impurities in rat plasma and its application to pharmacokinetic studies. SN Appl Sci. 2021;3:321. doi: 10.1007/s42452-021-04219-x.
Published
How to Cite
Issue
Section
Copyright (c) 2026 P. VASU BABU, D. AKILADEVI
This work is licensed under a Creative Commons Attribution 4.0 International License.